Cartography Biosciences key facts
as of Oct 2026- Operator of a biotechnology company intended to develop cancer therapies via precision medicine.
- Cartography Biosciences is valued at approximately $135.3M as of Oct 2026 (last reported valuation).
- It has raised $143.0M; the latest was Later Stage VC ($80.0M) in May 2025.
- Notable investors include Andreessen Horowitz, Gaingels, 8VC, Calm Ventures, Alexandria Venture Investments — 20 tracked in total.
- Status: Privately Held (backing).
Cartography Biosciences's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch Cartography Biosciences: the Monday email on marks, rounds and moves
Cartography Biosciences funding rounds
No funding rounds for Cartography Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Cartography Biosciences
20+Cartography Biosciences valuation
Cartography Biosciences's last reported valuation was $135 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Cartography Biosciences investors
20 investors are on record for Cartography Biosciences, including Andreessen Horowitz, Gaingels, 8VC and Calm Ventures. By type, the record holds 8 venture capital firms.
About Cartography Biosciences
Operator of a biotechnology company intended to develop cancer therapies via precision medicine. The company offers a platform-based cell therapy that utilizes single-cell analysis to identify novel Chimeric Antigen Receptor T-cell (CAR-T) targets, enabling pharmaceutical researchers and oncology developers to develop molecular biology and computational methods for the advancement of cancer immunotherapies.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2020
- Employees
- 48
- Website
- cartography.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.